The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Nous-209 has been developed using the Nouscom's viral vector platform
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Subscribe To Our Newsletter & Stay Updated
